[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers.
  • Recent advances have led to the identification of specific oncogenic products that are implicated in the malignant transformation of adult stem/progenitor cells into leukemic or tumorigenic and migrating cancer stem/progenitor cells during cancer progression.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


2. Sugie T, Takeuchi E, Kunishima F, Yotsumoto F, Kono Y: A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer; 2007;14(3):327-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor.
  • Carcinoma derived from the lining epithelial cells in malignant phyllodes tumor is a rare neoplasm of the breast and belongs to the category of carcinosarcoma.
  • We report a case of ductal carcinoma with squamous differentiation arising in malignant phyllodes tumor.
  • A breast tumor with a diameter of 6 cm was located mainly in the left outer area of the breast.
  • Mammography revealed a high-density mass with an irregular margin and ultrasound showed a cystic tumor.
  • A pathological diagnosis of ductal carcinoma with squamous differentiation was made by fine needle aspiration and a core needle biopsy.
  • She underwent neoadjuvant chemotherapy followed by a modified radical mastectomy with a skin flap.
  • Histopathological examination revealed that the invasive ductal carcinoma with squamous differentiation originated from the lining epithelial cells in malignant phyllodes tumor and that there was no transition area between the carcinomatous and the sarcomatous component.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Neoplasms, Multiple Primary / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690514.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Landolsi S, Gharbi O, Zrig M, Gribaa M, Njim L, Zakhama A, Abid A, Frébourg T, Ahmed SB: [Li Fraumeni syndrome: a case with multiple primary cancers and presenting a germline p53 mutation]. Ann Biol Clin (Paris); 2010 May-Jun;68(3):346-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le syndrome de Li Fraumeni: à propos d'un cas familial avec cancers multiples et présentant une mutation germinale du gène p53.
  • Li Fraumeni Syndrome (LFS) is a rare autosomal disorder characterized by a familial clustering of tumors.
  • At the age of 31 years, the patient was operated of bladder papillary superficial carcinoma; five years later, he was treated for a high grade pleomorphe sarcoma of the left thigh and treated by surgery, adjuvant chemotherapy and radiotherapy.
  • At the age of 38 years, after abdominal pain, radiologic examination reveled pancreatic tumor with bone and lymphatic metastases.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20478780.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Albornoz López R, Fernández García MI, Pérez Rodrigo I: [Topical interferon alpha 2 beta therapy in the management of conjunctival intraepithelial neoplasia]. Farm Hosp; 2007 Nov-Dec;31(6):382-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical interferon alpha 2 beta therapy in the management of conjunctival intraepithelial neoplasia].
  • [Transliterated title] Administración tópica de interferón alpha-2b como tratamiento de una neoplasia intraepitelial conjuntival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Farm Hosp. 2009 Nov-Dec;33(6):335-6 [20038393.001]
  • (PMID = 18348671.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


5. Jocham D, Durek C: [Treatment of superficial bladder tumor]. Urologe A; 2001 Nov;40(6):460-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of superficial bladder tumor].
  • [Transliterated title] Behandlung des oberflächlichen Harnblasentumors.
  • Every year in Germany approximately 12,000 people are afflicted by superficial carcinoma of the urinary bladder.
  • The goal of optimal therapy, therefore, is not only to cure the patients but also to lower the high rate of recurrence by appropriate prophylaxis.
  • After transurethral resection, treatment options include various topical modalities of instillation therapy, e.g., chemotherapy or immunotherapy.
  • The individual decision on which treatment modality is chosen should be based on the risk of relapse and the progression of the tumor.
  • This depends on tumor stage, degree of differentiation, and the presence of recurrence.
  • Some treatment options, such as instillation of bacillus Calmette-Guérin, have been validated by large randomized studies in the sense of evidence-based medicine.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. BCG Vaccine / administration & dosage. Combined Modality Therapy. Cystoscopy. Electrocoagulation. Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760351.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


6. Rodríguez-Pérez C, Del Campo Z, Wolley-Dod C, Gris O: [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2002 Dec;77(12):685-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia].
  • [Transliterated title] Tratamiento tópico con mitomicina C en la neoplasia intraepitelial córneo-conjuntival de gran espesor.
  • CASE REPORT: We present a case of recurrent conjunctival intraepithelial neoplasia, treated previously on two occasions with excisional biopsy.
  • Although the lesion was considerably raised, topical treatment with mitomycin-C 0.04% was applied, achieving the complete regression of the tumor.
  • DISCUSSION: Topical mitomycin-C acts at the ocular surface.
  • However, successive treatment cycles can achieve complete regression, even in considerably thick tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Epithelium, Corneal / pathology. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12471516.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


7. Sur RK, Nayler S, Ahmed SN, Donde B, Uijs RR, Cooper K, Giraud A: Angiosarcomas--clinical profile, pathology and management. S Afr J Surg; 2000 May;38(1):13-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of these patients had received prior radiotherapy or chemotherapy which would have predisposed them to the formation of an angiosarcoma.
  • Five of the 6 were confirmed as having angiosarcomas, while 1 patient was found to have a peripheral neuro-epithelial tumour.
  • Four patients had angiosarcomas of the breast, while there was 1 patient each with angiosarcoma of the skin, intestine and brain.
  • Postoperative radiotherapy was given in cases of incomplete excision, patient refusal of radical surgery or gross tumour.
  • In 1 patient follow-up details were not available as he did not return for treatment.
  • Angiosarcomas are aggressive malignant tumours arising from the endothelial cells.
  • Complete surgical excision is the treatment of choice in the management of this aggressive disease, which has a poor prognosis.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Hemangiosarcoma / pathology. Hemangiosarcoma / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Biopsy. Causality. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. South Africa / epidemiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12365113.001).
  • [ISSN] 0038-2361
  • [Journal-full-title] South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • [ISO-abbreviation] S Afr J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Weisser H, Hartschuh W, Greiner A, Bischof M, Enk A, Helmbold P: [Merkel cell carcinoma--clinically often misjudged]. Dtsch Med Wochenschr; 2007 Jul 30;132(30):1581-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma--clinically often misjudged].
  • Merkel cell carcinoma is a rare, rapidly growing, highly malignant dermal tumor which occurs preferentially on light-exposed skin in advanced age.
  • The course of the disease is frequently characterized by the occurrence of lymph node metastases and local recurrences, even in the first year after removal of the primary tumour.
  • The five-year overall survival rate is only about 65 %, despite rigorous therapy.
  • The diagnosis is confirmed immunohistochemically by neuroendocrine and epithelial markers.
  • The excision of the primary tumor is regarded as first-line therapy.
  • Adjuvant chemotherapy can be applied in this stage, as in small-cell bronchial carcinoma.
  • Despite good response to radiatiotherapy and chemotherapy, with at least prolonged recurrence-free intervals, Merkel cell carcinoma is rarely curable at the distant metastasizing stage.
  • Individually defined, aggressive treatment,including radiatiotherapy, may in future considerably improve the prognosis, especially in the early stages of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628844.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


10. Schwab R, Schneider C, Junge K, Stumpf M, Becker HP, Schumpelick V: [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity]. Chirurg; 2004 Feb;75(2):200-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity].
  • The solitary fibrous tumor (SFT) is a very rare and usually benign neoplasm.
  • This tumor is mostly located in the thoracic cavity, but it has also been reported in numerous sites including liver, skin, and meninges.
  • Solitary fibrous tumors consistently express CD 34 and react negatively to epithelial markers.
  • This absence of expression of epithelial markers, especially cytokeratin, is also useful to distinguish these rare entities from sarcomatous mesotheliomas.
  • The treatment of choice for solitary fibrous tumors is extensive surgical resection.
  • Up to now there is no evidence that radiation and chemotherapy are effective.
  • One-half of the patients with malignant tumors can be cured; the rest develop recurrences and metastases more often.
  • [MeSH-major] Incidental Findings. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Pleura / pathology. Pleura / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2002 Aug;43(4):559-61 [12124574.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Oct;259(9):470-3 [12386749.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):213-9 [10380040.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):185-9 [11167110.001]
  • [Cites] Chirurg. 1999 Aug;70(8):949-52 [10460294.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):47-52 [9589464.001]
  • [Cites] Thorax. 1991 Dec;46(12):930-1 [1792643.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):521-5 [11201008.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):63-8 [10665915.001]
  • [Cites] Cancer. 1979 Oct;44(4):1465-75 [498021.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • (PMID = 14991184.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Yücesoy G, Kus E, Cakiroglu Y, Muezzinoglu B, Yildiz K, Yucesoy I: Primary malignant melanoma of the cervix: report of a case. Arch Gynecol Obstet; 2009 Apr;279(4):573-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma of the cervix: report of a case.
  • BACKGROUND: To present a case of primary malignant melanoma of the cervix.
  • Histopathology showed a malignant neoplasm with increased vascularity, indicating the possibility of a primary uterine cervical melanoma.
  • Diagnosis of malignant melanoma was confirmed with immunohistochemistry, which showed diffuse positive reactions for S-100 protein and HBM-45, with no reaction for epithelial markers, namely cytokeratin AE1/AE3 and epithelial membrane antigen.
  • An extensive search for a melanotic lesion in skin and in uveal tract was performed to verify the distinct site of melanoma.
  • The tumor was stage IB1 according to the International Federation of Gynecology and Obstetrics classification.The patient underwent radical Wertheim-Meigs hysterectomy, bilateral salpingo-oopherectomy, and retroperitoneal pelvic lympadenectomy.
  • Radiotherapy or chemotherapy was not performed in the postoperative period.
  • CONCLUSION: Primary malignant melanoma of the cervix is a rare cervical malignancy.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726108.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Weiss C, Sauer R, Rödel C: [Radiochemotherapeutic options for bladder cancer]. Aktuelle Urol; 2008 Mar;39(2):123-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical cystectomy remains the standard of care for muscle-invasive bladder cancer, while for high-risk superficial carcinoma an organ-preserving approach, including transurethral resection (TUR) and intravesical therapy, is recommended.
  • This review summarizes the radiochemotherpeutic options for high risk T1 or muscle-invasive bladder cancer - as an alternative for/or neoadjuvant therapy before radical surgery.
  • Multimodality therapy, including TUR, radiation, and chemotherapy, is associated with recurrence and progression rates of 30 % and 15 %, respectively, in high-risk T1 bladder cancer.
  • [MeSH-major] Chemotherapy, Adjuvant. Cystectomy / methods. Radiotherapy, Adjuvant. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Bridged Compounds / therapeutic use. Cisplatin / therapeutic use. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Multicenter Studies as Topic. Neoadjuvant Therapy. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Risk Factors. Salvage Therapy. Taxoids / therapeutic use. Time Factors. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379965.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 45
  •  go-up   go-down


13. Noguchi H, Naomoto Y, Kondo H, Haisa M, Yamatsuji T, Shigemitsu K, Aoki H, Isozaki H, Tanaka N: Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech; 2000 Dec;10(6):343-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma.
  • Esophageal superficial carcinoma safely can be resected surgically or endoscopically.
  • We evaluated indications for endoscopic mucosal resection (EMR) and optimal treatment modality for superficial carcinoma of the esophagus based on clinical and pathologic analyses.
  • Between January 1, 1984, and September 30, 1999, 113 patients with superficial cancer of the esophagus underwent surgical or endoscopic resection (n = 33 patients, 36 lesions).
  • Mucosal and submucosal cancers were classified to be epithelial layer (m1), proper mucosal layer (m2), muscularis mucosae (m3), upper third of the submucosal level (sm1), middle third of the submucosal layer (sm2), or the lower third of the submucosal level (sm3) cancers, according to criteria of the Japanese Society for Esophageal Disease.
  • Ten patients also received radiotherapy, chemotherapy, or esophagectomy with lymph node dissection after use of EMR.
  • No such combination therapy was administered in six patients with m3 lesions, but without lymph vessel invasion.
  • All patients treated with use of EMR, including patients with m3 cancer who did not receive additional treatment, are living without recurrence.
  • Local resection with use of EMR could be regarded to be the preferred treatment of superficial esophageal cancers limited to the lamina propria mucosae.
  • Endoscopic mucosal resection also could be regarded to be the preferred treatment of m3 cancer without lymph vessel invasion.
  • Use of additional therapy, such as radiotherapy, allows the use of EMR for m3 cancer with lymph vessel invasion or sm1 cancers.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / standards. Esophagoscopy / standards. Mucous Membrane / surgery. Patient Selection
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147906.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Suárez C, Rodrigo JP, Ferlito A, Devaney KO, Rinaldo A: Merkel cell carcinoma of the head and neck. Oral Oncol; 2004 Sep;40(8):773-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the head and neck.
  • Merkel cell carcinoma (MCC) is a rare neuroendocrine neoplasm of the skin.
  • The tumor most frequently affects elderly patients, with a preference for the head and neck.
  • A significant proportion of MCC have been reported to occur in intimate association with malignant epithelial neoplasms.
  • The genetic mechanisms underlying the development and tumor progression of MCC are poorly understood, sharing pathogenetic mechanisms with other neoplasms of neural crest derivation.
  • Complete surgical resection is the mainstay of treatment of the primary tumor.
  • Tumor resections are recommended to include a 2-3-cm tumor-free margin around the primary lesion when possible, but this is often difficult to achieve in the head and neck, where Mohs micrographic surgery has proved to be effective.
  • The role of adjuvant radiation therapy is controversial.
  • The role of adjuvant chemotherapy in diminishing the risk of subsequent systemic recurrence in patients with positive nodes remains undefined.
  • Overall response rates to combination chemotherapy for surgically unresectable distant metastatic disease are generally high, although responses are transient.
  • [MeSH-major] Carcinoma, Merkel Cell. Head and Neck Neoplasms. Skin Neoplasms
  • [MeSH-minor] Chromosome Aberrations. Female. Humans. Immune Tolerance. Male. Prognosis. Sentinel Lymph Node Biopsy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288830.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


15. Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G: Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2006 Dec;17(12):1835-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors.
  • The median time to progression was 4.6 months and the median survival 9.5 months.
  • Twenty-two patients (41.5%) completed all cycles of treatment.
  • CONCLUSION: The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma.
  • Randomized studies are needed to explore the role of celecoxib in combination with chemotherapy or as maintenance treatment in these patients.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980601.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


16. Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H: Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol; 2004 Jul;172(1):66-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup.
  • PURPOSE: We present long-term results of the percutaneous approach and resection of upper urinary tract transitional cell carcinoma, and we evaluate the prognostic factors related to recurrence.
  • MATERIALS AND METHODS: A total of 34 patients underwent primary percutaneous resection of an upper urothelial tumor.
  • We treated the patients with a superficial tumor that was completely resected macroscopically.
  • Adjuvant topical chemotherapy or immunotherapy was administered.
  • Ureteroscopy and computerized tomography were obtained when clinically indicated.
  • RESULTS: With a mean followup of 51 months ipsilateral recurrence developed in 41.2%.
  • Median time to recurrence was 24 months.
  • There was a trend of recurrence in patients with multifocal tumors (OR 2.66, 95% CI 0.07-1.92), history of bladder carcinoma in situ (OR 2.4, 95% CI 1.61-3.74), tumor in renal pelvis (OR 6.45, 95% CI 0.01-1.46) and multiple tumor locations (OR 6.53, 95% CI 0.01-1.54).
  • CONCLUSIONS: The percutaneous approach to renal urothelial tumor should be considered a valid option with a good long-term outcome.
  • Recurrence is not uncommon and, as transitional cell carcinoma superficial bladder cancer it may be treated with endourological maneuvers or radical surgery, but with the obligation to a long lasting, strict surveillance.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urologic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Ureteroscopy. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201739.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


17. Schleier P, Hyckel P, Berndt A, Bode HP, Albrecht V, Hindermann W, Kosmehl H, Zenk W, Schumann D: Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol; 2004 May;130(5):279-84
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients.
  • Among other effects, there is a 50-250 times increased risk of developing malignant skin tumours.
  • Because these malignomas are known to develop particularly aggressivly, there is a special need for an efficient therapy.
  • Here we demonstrate the treatment response to aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) in these patients.
  • After intervals of 2 weeks, 4 weeks, and 12 weeks, therapeutic efficacy was assessed.
  • CONCLUSIONS: ALA-PDT is a valuable therapeutic alternative for the treatment of multifocal skin tumours in organ-transplanted patients.
  • Furthermore, we see a growing role of ALA-PDT also for patients with frequently relapsing tumours of the skin with known genetically determined tumourigenesis (Gorlin-Goltz syndrome).
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Facial Neoplasms / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy. Transplants
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Humans. Keratosis / drug therapy. Keratosis / virology. Middle Aged. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • [Cites] Chest Surg Clin N Am. 2001 Nov;11(4):829-39 [11780298.001]
  • [Cites] Liver Transpl Surg. 1999 Sep;5(5):451-3 [10477847.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):384-8 [9458076.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2373-9 [7757989.001]
  • [Cites] J Clin Laser Med Surg. 1995 Oct;13(5):325-8 [10163495.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S13-8 [12060512.001]
  • [Cites] Liver Transpl. 2001 Nov;7(11):971-5 [11699033.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S25-9 [12060514.001]
  • [Cites] Mund Kiefer Gesichtschir. 2001 Mar;5(2):94-7 [11372186.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):87-96 [11734119.001]
  • [Cites] Photochem Photobiol. 1995 Nov;62(5):906-13 [8570730.001]
  • [Cites] Urol Res. 2001 Jun;29(3):205-9 [11482448.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S3-11 [12060511.001]
  • [Cites] Cutis. 2002 Feb;69(2):140-2 [11868977.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):952-6 [12060136.001]
  • [Cites] Laryngoscope. 2001 Dec;111(12):2205-13 [11802027.001]
  • [Cites] Int Arch Occup Environ Health. 2002 Apr;75(4):272-6 [11981662.001]
  • [Cites] BJU Int. 2002 May;89(7):665-70 [11966622.001]
  • [Cites] Gene Ther. 1999 Oct;6(10):1742-50 [10516724.001]
  • [Cites] J Photochem Photobiol B. 1996 Jun;34(1):13-9 [8765659.001]
  • [Cites] Clin Transpl. 2000;:193-202 [11512313.001]
  • [Cites] Mund Kiefer Gesichtschir. 2001 Mar;5(2):98-104 [11372187.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):25-32 [9334805.001]
  • [Cites] Mol Ther. 2000 Jan;1(1):56-62 [10933912.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Lasers Surg Med. 2001;29(4):314-22 [11746108.001]
  • [Cites] Hautarzt. 2001 Jul;52(7):677-85 [11475655.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):561-6 [10662801.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):246-53 [11180000.001]
  • [Cites] Mund Kiefer Gesichtschir. 1999 Jul;3(4):205-9 [10474266.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2001 Nov;15(6):550-4 [11843215.001]
  • [Cites] Arch Dermatol. 1986 Dec;122(12):1391-5 [3789772.001]
  • [Cites] Am J Clin Dermatol. 2001;2(4):229-37 [11705250.001]
  • [Cites] Urol Res. 2001 Dec;29(6):396-405 [11828993.001]
  • [Cites] Ann Transplant. 1997;2(4):28-32 [9869876.001]
  • [Cites] J Photochem Photobiol B. 1997 Oct;40(3):313-9 [9372622.001]
  • (PMID = 14997383.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


18. Pieras E, Palou J, Salvador J, Rosales A, Marcuello E, Villavicencio H: Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol; 2003 Aug;44(2):222-5; discussoion 225
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
  • PURPOSE: To assess the bladder preservation rate and cancer-specific survival after conservative treatment of superficial relapses in invasive tumors after bladder preservation.
  • MATERIAL AND METHODS: Fifty-one patients with invasive bladder tumor (T2) were treated using transurethral resection (TUR) followed by three cycles of systemic chemotherapy (carboplatin-vinblastine).
  • After three weeks, an endoscopic reappraisal was made including deep TUR of the site of the original tumor and multiple cold cup biopsies.
  • RESULTS: With a median follow-up of 63 months, 18 patients recurred as superficial TCC tumor (43%).
  • Fourteen patients with high grade superficial recurrence were treated with TUR and Bacillus Calmette-Guerin (BCG) instillations; two patients (G2-3 T1) with TUR as well as endovesical mytomicine, and two patients with low grade recurrence with only TUR.
  • With a median follow-up of 44 months after TUR of first superficial relapse, there was only one case with progression of the disease without any evidence of bladder tumor.
  • Two cystectomies were made due to carcinoma in situ (Cis) persistence and high grade superficial recurrence.
  • Eighty-three percent of the patients who had superficial recurrence retained their bladders, with 94% cancer-specific survival.
  • CONCLUSIONS: A very strict follow-up is mandatory due to the high rate of superficial relapses (43%).
  • Cis is the most frequent type of superficial recurrence.
  • Superficial recurrences in bladder preservation may be treated with TUR and BCG instillations when they are high grade and and/or associated with Cis.
  • Superficial recurrences do not imply a worse prognosis for bladder preservation or cancer-specific survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Neoplasm Recurrence, Local / diagnosis. Transurethral Resection of Prostate. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] BCG Vaccine / administration & dosage. Carboplatin / administration & dosage. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Combined Modality Therapy. Cystectomy. Disease Progression. Follow-Up Studies. Humans. Lymphatic Metastasis. Muscle, Smooth / pathology. Neoplasm Staging. Outcome and Process Assessment (Health Care). Prognosis. Survival Analysis. Urethra / surgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12875942.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BCG Vaccine; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


19. Lu J, Xue LY, Lu N, Zou SM, Liu XY, Wen P: Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus; 2010 Feb;23(2):153-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases.
  • Primary esophageal small cell carcinoma (PESCC) is a relatively rare and aggressive tumor with poor prognosis.
  • Although 5-year survival rate of superficial squamous cell carcinoma of the esophagus can be 86.1%, 5-year survival rate of superficial PESCC is still relatively low.
  • This study mainly retrospectively analyzed clinicopathological and immunohistochemical features of 15 cases of superficial PESCC in our hospital from 1990 to 2004, in order to find suitable diagnostic markers and applicable therapies for this disease.
  • The records mainly included presenting symptoms, demographics, diagnostic method, histopathology, follow-up, and therapy.
  • Incidence of superficial PESCC accounted for 4.8% of that of superficial carcinoma of the esophagus during the same period.
  • The median survival time was 19 months and mean survival time was 23.7 months after diagnosis.
  • Our study suggested that PESCC was a rare and aggressive tumor with high malignancy.
  • Superficial PESCC had rapid progression and poor prognosis compared with superficial squamous cell carcinoma of the esophagus at the same stage.
  • The systemic therapy based on combination of postoperative chemotherapy and radiotherapy might be an effective approach for the treatment of superficial PESCC as a systemic disease.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515193.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / CK-34 beta E12; 0 / Chromogranin A; 0 / Keratin-13; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


20. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Two tumors showed weak, focal cytoplasmic positivity for CD30, and 1 for epithelial membrane antigen.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Tumor size may be a prognostic factor.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Dummer R, Beyeler M, Morcinek J, Burg G: [Cutaneous neoplasms]. Praxis (Bern 1994); 2003 Sep 3;92(36):1470-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The skin is the organ most commonly affected by malignancies.
  • Various cancers of the skin show a dramatic increase in incidence over the last decades.
  • Epithelial skin tumors are most frequently, e.g., basal cell carcinoma and the squamous cell carcinoma with its precursors, the actinic keratoses.
  • Melanoma, which is extremely difficult to treat in advanced tumor stages, is dreaded.
  • Besides that, there are other epithelial malignant diseases, e.g.
  • Morbus Bowen and adnexal tumors originating from the skin appendices.
  • Mesenchymal malignant neoplasias such as Morbus Kaposi, angiosarcomas and other dermal sarcomas, are rare.
  • Since the majority of malignant neoplasms is removable and curable by a simple surgical intervention, the knowledge of the different skin tumors is essential for non-dermatologist.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Melanoma. Skin Neoplasms
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biopsy. Bowen's Disease / diagnosis. Bowen's Disease / drug therapy. Bowen's Disease / radiotherapy. Bowen's Disease / surgery. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / surgery. Carcinoma, Merkel Cell / therapy. Clinical Trials as Topic. Combined Modality Therapy. Cryotherapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. HIV Infections / complications. Hemangiosarcoma / diagnosis. Humans. Immunotherapy. Keratosis / diagnosis. Keratosis / drug therapy. Keratosis / surgery. Lymph Node Excision. Lymphatic Metastasis. Lymphoma / classification. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / radiotherapy. Lymphoma / surgery. Male. Neoplasm Recurrence, Local. Photochemotherapy. Randomized Controlled Trials as Topic. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / surgery. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14526630.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 22
  •  go-up   go-down


22. Javaid B, Watt P, Krasner N: Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci; 2002;17(1):51-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study.
  • Barrett's oesophagus is a premalignant condition in which stratified squamous type mucosa of the normal oesophagus is replaced by specialised intestinal type columnar mucosa.
  • Oesophageal resection was previously considered to be the treatment of choice for high-grade dysplasia or superficial carcinoma arising in this columnar-lined mucosa.
  • We treated four patients with Barrett's oesophagus and high-grade dysplasia, and one patient with superficial oesophageal carcinoma with photodynamic therapy (PDT) using an argon-pumped dye laser light (652 nm).
  • There is no evidence of recurrence in the patient who had oesophageal carcinoma, at 27 months follow-up.
  • We conclude that mTHPC is useful as a photosensitiser for PDT in the management of Barrett's oesophagus with high-grade dysplasia or superficial carcinoma and the Paterson lamp is a potential alternative light source for PDT.
  • [MeSH-major] Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lasers Med Sci. 2002;17(2):135 [12143833.001]
  • (PMID = 11845368.001).
  • [ISSN] 0268-8921
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


23. Babilas P, Schreml S, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed; 2010 Jun;26(3):118-32
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in dermatology: state-of-the-art.
  • Photodynamic therapy (PDT) has become an established treatment modality for dermatooncologic conditions like actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and superficial basal cell carcinoma.
  • Aesthetic indications like photo-aged skin or sebaceous gland hyperplasia complete the range of applications.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584250.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


24. Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM: Bladder cancer stem cells. Curr Stem Cell Res Ther; 2010 Dec;5(4):387-95
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cells are undifferentiated cells that renew themselves while simultaneously producing differentiated tissue- or organspecific cells through asymmetric cell division.
  • The appreciation of the importance of stem cells in normal tissue biology has prompted the idea that cancers may also develop from a progenitor pool (the "cancer stem cell (CSC) hypothesis"), and this idea is gaining increasing acceptance among scientists.
  • CSCs are sub-populations of cancer cells responsible for tumor initiation, differentiation, recurrence, metastasis, and drug resistance.
  • Recently, the tissue-specific stem cells of the normal urothelium have been proposed to reside in the basal layer, and investigators have isolated phenotypically similar populations of cells from urothelial cancer cell lines and primary tumors.
  • Herein, we review the CSC hypothesis and apply it to explain the development of the two different types of bladder cancer: noninvasive ("superficial") carcinoma and invasive carcinoma.
  • We also examine potential approaches to identify CSCs in bladder cancer as well as therapeutic applications of these findings.
  • Herein, we identify and answer some of these questions to help readers better understand bladder cancer development and identify reasonable therapeutic strategy for targeting stem cells.
  • [MeSH-major] Carcinoma / pathology. Neoplastic Stem Cells / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Disease Progression. Humans. Models, Biological. Neoplasm Invasiveness. Organ Specificity. Stem Cell Niche

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20955163.001).
  • [ISSN] 2212-3946
  • [Journal-full-title] Current stem cell research & therapy
  • [ISO-abbreviation] Curr Stem Cell Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology--an update. Photodermatol Photoimmunol Photomed; 2005 Jun;21(3):142-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in dermatology--an update.
  • Topical photodynamic therapy (PDT) is a well-established treatment modality which has mainly shown to be effective for dermatooncologic conditions like actinic keratoses (AK), Bowen's disease, in situ squamous cell carcinoma and superficial basal cell carcinoma (BCC).
  • These drugs do not induce strong generalized cutaneous photosensitization like the systemically applied porphyrins or their derivatives.
  • Depending on the applied light dose and the concentration of the photosensitizer either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving the inflammatory conditions occur.
  • Treating superficial oncologic lesions (tumor thickness <2-3 mm) cure rates achieved by PDT are equal to the cure rates of the respective standard therapeutic procedure.
  • The benefits of PDT are the low level of invasiveness and the excellent cosmetic results after treatment.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888131.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 56
  •  go-up   go-down


26. Babilas P, Szeimies RM: The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol; 2010 Oct;145(5):613-30
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of photodynamic therapy in dermatology.
  • In dermatology, topical photodynamic therapy (PDT) is a well established treatment modality which has mainly shown to be effective for dermato-oncologic conditions like actinic keratosis, Bowen's disease, in-situ squamous cell carcinoma and superficial basal cell carcinoma.
  • However, a therapeutical benefit of PDT is also evident for inflammatory dermatoses like localized scleroderma, acne vulgaris and granuloma annulare as well as for aesthetic indications like photo aged skin or sebaceous gland hyperplasia.
  • These drugs do not induce strong generalized cutaneous photosensitization like the systemically applied porphyrins or their derivatives.
  • Depending on the applied light dose and the concentration of the photosensitizer either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving the inflammatory conditions occur.
  • Treating superficial oncologic lesions (tumor thickness < 2-3 mm) cure rates achieved by PDT are equal to the cure rates of the respective standard therapeutic procedure.
  • The benefits of PDT are the low level of invasiveness and the excellent cosmetic results after treatment.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Carcinoma, Basal Cell / drug therapy. Cosmetic Techniques. Humans. Keratosis, Actinic / drug therapy. Light. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Neoplasms / drug therapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930696.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


27. Drechsler A, Kirch W: [Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension]. Dtsch Med Wochenschr; 2010 Oct;135(40):1968-70
Hazardous Substances Data Bank. ETHAMBUTOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTORY AND ADMISSION FINDINGS: A 71-year-old patient with a superficial carcinoma of the urinary bladder and high risk of recurrence was treated with intravesical instillation of Bacillus Calmette-Guérin (BCG) after transurethral resection.
  • As a complication of the catheterization during BCG-instillation therapy the patient suffered from tuberculosis.
  • The patient received a tuberculosis triple-therapy including rifampicin 600 mg once daily, isoniazid 300 mg once daily and ethambutol 400 mg thrice daily.
  • The existing arterial hypertension had successfully been controlled by 3.75 mg bisoprolol medication once daily for the last 15 years.
  • An increase of blood pressure and cardiac arrhythmia were seen after combining the β1-receptor blocker treatment with the triple-therapy.
  • TREATMENT AND COURSE: The dosage of bisoprolol was changed to 3.75 mg in the morning and additional 1.875 mg in the evening.
  • CONCLUSION: Rifampicin is one of the best known potent enzyme inducing drugs.
  • The enzyme induction enhance the hepatic bisoprolol metabolism, hence the metabolic clearance of the drug increased.
  • A dosage adjustment of bisoprolol is necessary if the clinical status of the patient requires treatment with the antituberculosis drug rifampicin.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / adverse effects. Antihypertensive Agents / adverse effects. Antitubercular Agents / adverse effects. BCG Vaccine / administration & dosage. BCG Vaccine / adverse effects. Bisoprolol / adverse effects. Carcinoma, Transitional Cell / drug therapy. Ethambutol / adverse effects. Isoniazid / adverse effects. Neoplasm Recurrence, Local / drug therapy. Rifampin / adverse effects. Tuberculosis, Urogenital / drug therapy. Tuberculosis, Urogenital / etiology. Urinary Bladder Diseases / drug therapy. Urinary Bladder Diseases / etiology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Blood Pressure / drug effects. Cardiac Complexes, Premature / chemically induced. Combined Modality Therapy. Cytochrome P-450 CYP3A / drug effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Interactions. Drug Therapy, Combination. Electrocardiography / drug effects. Enzyme Induction / drug effects. Humans. Male. Metabolic Clearance Rate / drug effects

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. ISONIAZID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20922637.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antihypertensive Agents; 0 / Antitubercular Agents; 0 / BCG Vaccine; 8G167061QZ / Ethambutol; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin; Y41JS2NL6U / Bisoprolol
  •  go-up   go-down


28. Schmitt D: [The Langerhans cell: from in vitro production to use in cellular immunotherapy]. J Soc Biol; 2001;195(1):69-74
HIV InSite. treatment guidelines - HIV InSite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La cellule de Langerhans: de la production in vitro à l'utilisation en immunothérapie cellulaire.
  • Langerhans cells are present with epithelial cells in the epidermis, bronchi and mucosae.
  • They are actively involved in skin lesions of allergic contact dermatitis or atopic dermatitis, in cancer immunosurveillance and are infected by HIV in AIDS.
  • The possibility to obtain from the blood, the circulating progenitors of dendritic cells and the subsequent possibility to harvest a large number of these cells through in vitro culture using growth factors, have given rise to several very interesting therapeutic perspectives, especially in the field of anti-cancer immunotherapy.
  • In dermatology advanced studies have concerned malignant melanomas.
  • These results open a particularly interesting perspective in the field of cancer treatment.
  • [MeSH-minor] Antigen Presentation. Antigens, Neoplasm / immunology. Blood Cells / cytology. Cell Differentiation. Cells, Cultured / drug effects. Cells, Cultured / immunology. Cells, Cultured / transplantation. Clinical Trials as Topic. Dendritic Cells / immunology. Dendritic Cells / transplantation. Fetal Blood / cytology. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / drug effects. Humans. Immunophenotyping. Interleukin-4 / pharmacology. Melanoma / immunology. Melanoma / therapy. Monocytes / cytology. Monocytes / drug effects. Skin / immunology. Transforming Growth Factor beta / pharmacology. Treatment Outcome. Tumor Necrosis Factor-alpha / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11530504.001).
  • [ISSN] 1295-0661
  • [Journal-full-title] Journal de la Société de biologie
  • [ISO-abbreviation] J. Soc. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 45
  •  go-up   go-down


29. Lehmann P: Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol; 2007 May;156(5):793-801
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer.
  • Methyl aminolaevulinate-photodynamic therapy (MAL-PDT) has advanced the management of nonmelanoma skin cancer (NMSC), providing a treatment option for actinic keratosis (AK), basal cell carcinoma [both superficial (sBCC) and nodular (nBCC)] and Bowen's disease, with good clinical outcomes, low recurrence rates and enhanced cosmetic acceptability.
  • MAL-PDT specifically targets diseased cells, leaving healthy tissue unharmed.
  • This noninvasive treatment option is associated with minimal risk of scarring.
  • Moreover, systemic uptake of MAL is negligible and the local phototoxic reactions that often occur during treatment rapidly heal to produce excellent cosmetic results.
  • The side-effects of therapy, which are predominantly local phototoxic effects (burning, stinging and prickling sensations), are of mild-to-moderate intensity, of short duration and easily managed.
  • Overall, the efficacy and low risk of side-effects afforded by this therapy have resulted in high patient preference in clinical trials.
  • The current evidence base for MAL-PDT in the treatment of AK and NMSC is reviewed in this article.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419691.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 55
  •  go-up   go-down


30. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA, International Society for Photodynamic Therapy in Dermatology: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol; 2007 Jan;56(1):125-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.
  • Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular).
  • This article presents up-to-date, practical, evidence-based recommendations on the use of topical PDT using 5-aminolevulinic acid or methyl aminolevulinate for the treatment (and prevention) of nonmelanoma skin cancers.
  • Topical PDT is highly effective in the treatment of actinic keratoses, Bowen's disease, superficial and thin nodular basal cell carcinomas, with cosmesis typically superior to that achieved with existing standard therapies.
  • PDT may also be a means of preventing certain nonmelanoma skin cancers in immunosuppressed patients.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Australia / epidemiology. Basal Cell Nevus Syndrome / drug therapy. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Double-Blind Method. Humans. Immunocompromised Host. Incidence. Keratosis / drug therapy. Multicenter Studies as Topic. Patient Satisfaction. Photosensitivity Disorders / drug therapy. Randomized Controlled Trials as Topic. Skin Diseases / drug therapy. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190630.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 91
  •  go-up   go-down


32. Drechsler A, Kirch W: [Urinary bladder tuberculosis and bacillus calmette-guérin instillation: reduced efficacy of bisoprolol in hypertension]. Aktuelle Urol; 2010 Nov;41(6):372-4
Hazardous Substances Data Bank. RIFAMPIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTORY AND ADMISSION FINDINGS: A 71-year-old patient with a superficial carcinoma of the urinary bladder and high risk of recurrence was treated with intravesical instillation of Bacillus Calmette-Guérin (BCG) after transurethral resection.
  • As a complication of the catheterization during BCG-instillation therapy the patient suffered from tuberculosis.
  • The patient received a tuberculosis triple-therapy including rifampicin 600 mg once daily, isoniazid 300 mg once daily and ethambutol 400 mg thrice daily.
  • The existing arterial hypertension had successfully been controlled by 3.75 mg bisoprolol medication once daily for the last 15  years.
  • An increase of blood pressure and cardiac arrhythmia were seen after combining the β (1)-receptor blocker treatment with the triple-therapy.
  • TREATMENT AND COURSE: The dosage of bisoprolol was changed to 3.75 mg in the morning and additional 1.875 mg in the evening.
  • CONCLUSION: Rifampicin is one of the best known potent enzyme inducing drugs.
  • The enzyme induction enhance the hepatic bisoprolol metabolism, hence the metabolic clearance of the drug increased.
  • A dosage adjustment of bisoprolol is necessary if the clinical status of the patient requires treatment with the antituberculosis drug rifampicin.
  • [MeSH-major] Antihypertensive Agents / pharmacokinetics. Antihypertensive Agents / therapeutic use. Antitubercular Agents / adverse effects. Antitubercular Agents / therapeutic use. BCG Vaccine / administration & dosage. BCG Vaccine / adverse effects. Bisoprolol / pharmacokinetics. Bisoprolol / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Hypertension / drug therapy. Rifampin / adverse effects. Rifampin / therapeutic use. Tuberculosis, Urogenital / drug therapy. Tuberculosis, Urogenital / etiology. Urinary Bladder Diseases / drug therapy. Urinary Bladder Diseases / etiology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cytochrome P-450 CYP3A / metabolism. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Interactions. Drug Therapy, Combination. Enzyme Induction / drug effects. Humans. Male

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart ˙ New York.
  • (PMID = 21082517.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Antitubercular Agents; 0 / BCG Vaccine; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; VJT6J7R4TR / Rifampin; Y41JS2NL6U / Bisoprolol
  •  go-up   go-down


33. Fry A, Saleemi A, Griffiths M, Farrington K: Acute renal failure following intravesical bacille Calmette-Guérin chemotherapy for superficial carcinoma of the bladder. Nephrol Dial Transplant; 2005 Apr;20(4):849-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure following intravesical bacille Calmette-Guérin chemotherapy for superficial carcinoma of the bladder.
  • [MeSH-minor] Aged. Carcinoma in Situ / drug therapy. Humans. Male. Urinary Bladder Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772275.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down






Advertisement